Optipranolol

Open Angle Glaucoma, Ocular Hypertension
Treatment
4 FDA approvals
17 Active Studies for Optipranolol

What is Optipranolol

MetipranololThe Generic name of this drug
Treatment SummaryPropranolol is a medication used to treat irregular heartbeats, high blood pressure, and glaucoma. It works by blocking the action of adrenaline, a hormone that can cause these medical conditions.
OptiPranololis the brand name
Optipranolol Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
OptiPranolol
Metipranolol
1989
4

Approved as Treatment by the FDA

Metipranolol, otherwise known as OptiPranolol, is approved by the FDA for 4 uses like Ocular Hypertension and Open Angle Glaucoma (OAG) .
Ocular Hypertension
Helps manage Ocular Hypertension
Open Angle Glaucoma (OAG)
Helps manage Open Angle Glaucoma (OAG)
Open Angle Glaucoma
Helps manage Open Angle Glaucoma (OAG)
Ocular Hypertension
Helps manage Ocular Hypertension

Effectiveness

How Optipranolol Affects PatientsMetipranolol is a drug that helps lower pressure in the eye. It does not have any other effects on the body. It is used to treat ocular hypertension and open-angle glaucoma, conditions that can damage the optic nerve and cause vision loss. Metipranolol lowers pressure in the eye without affecting pupil size or the ability to see clearly at different distances.
How Optipranolol works in the bodyMetipranolol works by blocking the beta1 and beta2 adrenergic receptors. This reduces the amount of aqueous humor produced in the eye, as well as slightly increasing its outflow. However, it does not have a significant stimulating effect on the body or any significant local anesthetic or heart-depressing effects.

When to interrupt dosage

The prescribed dosage of Optipranolol is contingent upon the diagnosed condition. The extent of dosage relies upon the method of delivery, as detailed in the accompanying table.
Condition
Dosage
Administration
Open Angle Glaucoma
3.0 mg/mL,
, Solution / drops, Solution / drops - Ophthalmic, Ophthalmic
Ocular Hypertension
3.0 mg/mL,
, Solution / drops, Solution / drops - Ophthalmic, Ophthalmic

Warnings

Optipranolol Contraindications
Condition
Risk Level
Notes
Heart Failure
Do Not Combine
Atrioventricular Block
Do Not Combine
Asthma
Do Not Combine
symptomatic sinus bradycardia
Do Not Combine
Shock, Cardiogenic
Do Not Combine
Asthma
Do Not Combine
There are 20 known major drug interactions with Optipranolol.
Common Optipranolol Drug Interactions
Drug Name
Risk Level
Description
Aliskiren
Minor
Metipranolol may increase the hypotensive activities of Aliskiren.
Ambrisentan
Minor
Metipranolol may increase the hypotensive activities of Ambrisentan.
Angiotensin 1-7
Minor
Metipranolol may increase the hypotensive activities of Angiotensin 1-7.
Azilsartan medoxomil
Minor
Metipranolol may increase the hypotensive activities of Azilsartan medoxomil.
BQ-123
Minor
Metipranolol may increase the hypotensive activities of BQ-123.

Optipranolol Novel Uses: Which Conditions Have a Clinical Trial Featuring Optipranolol?

34 active investigations are assessing the potential of Optipranolol to mitigate Open Angle Glaucoma.
Condition
Clinical Trials
Trial Phases
Ocular Hypertension
10 Actively Recruiting
Phase 3, Phase 1, Phase 2, Not Applicable, Phase 4
Open Angle Glaucoma
10 Actively Recruiting
Phase 3, Not Applicable, Phase 4

Patient Q&A Section about optipranolol

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Metipranolol used for?

"This medicine is used to lower pressure in the eye that is caused by open-angle glaucoma or ocular hypertension. It is a beta-blocker."

Answered by AI

Is Metipranolol discontinued?

"As of right now, are there any brands or generic products of metipranolol still available on the market?"

Answered by AI

What is the generic name for timoptic?

"The drug Timoptic is called timolol in its generic form. The drug Xalatan is called latanoprost in its generic form."

Answered by AI

Clinical Trials for Optipranolol

Have you considered Optipranolol clinical trials? We made a collection of clinical trials featuring Optipranolol, we think they might fit your search criteria.Go to Trials
Have you considered Optipranolol clinical trials? We made a collection of clinical trials featuring Optipranolol, we think they might fit your search criteria.Go to Trials
Image of Department of Ophthalmology and Visual Sciences, University of Alabama at Birmingham in Birmingham, United States.

AI-Based Screening for Glaucoma

18+
All Sexes
Birmingham, AL
The goal of this clinical trial is to learn if implementation of an eye screening program at Federally Qualified Health Center (FQHC) clinics provides results that participants may have glaucoma, and/or other eye conditions (diabetic retinopathy, cataract, visual acuity impairment). The glaucoma screening will incorporate use of an artificial intelligence (AI)-assisted screening tool. This project is called AI-RONA. The main questions it aims to answer are: * How does this eye screening program compare to the rate of glaucoma and other eye conditions detected at other FQHC clinics where the screening program has not been implemented? * Do particpants who screen positive for these conditions adhere to the physician's recommendation for a follow-up examination by an optometrist or ophthalmologist? * Are referral rates for a follow-up comprehensive eye exam by an optometrist or ophthalmologist similar to those implemented by an ophthalmologist using telemedicine (that is, using the results of the screening to make a diagnosis remotely)? * What is the cost-effectiveness of the AI-assisted screening program in diagnosing glaucoma as compared to a physician-guided program? * Are participants completing the screening satisfied with it? * Are physicians at the FQHC clinics administering the screening satisfied with it? Participants will: * Undergo an ocular screening whose goal is to detect glaucoma, diabetic retinopathy, cataract, and/or impairment in visual acuity. If the screening indicates that participants may have these conditions, participants will be referred for a comprehensive eye examination by an optometrist or ophthalmologist. * Following the screening, participants and physicians will complete a survey on their satisfaction with the program.
Waitlist Available
Has No Placebo
Department of Ophthalmology and Visual Sciences, University of Alabama at BirminghamCynthia Owsley, PhD
Image of Ventura Ophthalmology /ID# 227585 in Ventura, United States.

XEN45 Gel Stent for Open-Angle Glaucoma

18+
All Sexes
Ventura, CA
Glaucoma is the second most common cause of blindness in the world, second only to cataracts. This study will assess how safe and effective a glaucoma gel stent is when implanted using the ab externo approach. Adverse events and intraocular pressure will be assessed. XEN45 is an approved device for the treatment of glaucoma implanted using the ab interno approach (inside the eye). XEN45 implanted using the ab externo approach (outside the eye) is being studied in this study. Approximately 65 participants aged 45 years or older with open-angle glaucoma will be enrolled in this study at approximately 22 sites in the United States. All participants will receive XEN45 implanted using the ab externo approach on Day 1 and will be followed for 12 months. Participants will attend regular visits during the study at a hospital or clinic. The safety and effect of the gel stent on your glaucoma will be checked by medical assessments and eye examinations.
Phase 3
Recruiting
Ventura Ophthalmology /ID# 227585 (+22 Sites)ABBVIE INC.AbbVie
Have you considered Optipranolol clinical trials? We made a collection of clinical trials featuring Optipranolol, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security